GPT and diabetes mellitus: The oral administration of APE significantly altered diabetes‐induced hepatorenal dysfunction, as indicated by a reduction in functional biomarkers of the liver (ALT, AST, and ALP) and kidney (BUN, uric acid, and Scr).